TOPLINE:

A retrospective study found that patients with mismatch repair (MMR)-deficient advanced or recurrent endometrial cancer had numerically longer overall survival (OS) than those with MMR-proficient tumours.

METHODOLOGY:

Researchers analysed 731 patients with advanced (n = 575) or recurrent (n = 156) endometrial cancer (mean age, 68.26 years; 81.66% White) using data from the UK Arcturis dataset between January 2000 and September 2023.

Patients were stratified on the basis of their MMR status as those with deficient MMR (5.75%), proficient MMR (16.96%), or unknown MMR status (77.29%).

The most common treatment for MMR-deficient patients was surgery (30.95%), and that for MMR-proficient patients was surgery plus chemotherapy (24.19%). Chemotherapy was administered as a second-l

See Full Page